Abstract
Dyskinesia and motor fluctuations affect up to 90% of patients with Parkinson's disease (PD) within ten years of L-DOPA pharmacotherapy, and represent a major challenge to a successful clinical management of this disorder. There are currently two main treatment options for these complications, namely, deep brain electrical stimulation or continuous infusion of dopaminergic agents. The latter is achieved using either subcutaneous apomorphine infusion or enteric L-DOPA delivery. Some patients also benefit from the antidyskinetic effect of amantadine as an adjunct to L-DOPA treatment. Ongoing research in animal models of PD aims at discovering additional, novel treatment options that can either prevent or reverse dyskinesia and motor fluctuations. Alternative methods of continuous L-DOPA delivery (including gene therapy), and pharmacological agents that target nondopaminergic receptor systems are currently under intense experimental scrutiny. Because clinical response profiles show large individual variation in PD, an increased number of treatment options for dyskinesia and motor fluctuations will eventually allow for antiparkinsonian and antidyskinetic therapies to be tailor-made to the needs of different patients and/or PD subtypes.
Keywords: Parkinson's disease, motor fluctuations, dyskinesia, motor complications, basal ganglia, glutamate, serotonin, rodent, non-human primate, L-DOPA
CNS & Neurological Disorders - Drug Targets
Title:Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
Volume: 10 Issue: 6
Author(s): M. A. Cenci, K. E. Ohlin and P. Odin
Affiliation:
Keywords: Parkinson's disease, motor fluctuations, dyskinesia, motor complications, basal ganglia, glutamate, serotonin, rodent, non-human primate, L-DOPA
Abstract: Dyskinesia and motor fluctuations affect up to 90% of patients with Parkinson's disease (PD) within ten years of L-DOPA pharmacotherapy, and represent a major challenge to a successful clinical management of this disorder. There are currently two main treatment options for these complications, namely, deep brain electrical stimulation or continuous infusion of dopaminergic agents. The latter is achieved using either subcutaneous apomorphine infusion or enteric L-DOPA delivery. Some patients also benefit from the antidyskinetic effect of amantadine as an adjunct to L-DOPA treatment. Ongoing research in animal models of PD aims at discovering additional, novel treatment options that can either prevent or reverse dyskinesia and motor fluctuations. Alternative methods of continuous L-DOPA delivery (including gene therapy), and pharmacological agents that target nondopaminergic receptor systems are currently under intense experimental scrutiny. Because clinical response profiles show large individual variation in PD, an increased number of treatment options for dyskinesia and motor fluctuations will eventually allow for antiparkinsonian and antidyskinetic therapies to be tailor-made to the needs of different patients and/or PD subtypes.
Export Options
About this article
Cite this article as:
A. Cenci M., E. Ohlin K. and Odin P., Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease, CNS & Neurological Disorders - Drug Targets 2011; 10 (6) . https://dx.doi.org/10.2174/187152711797247885
DOI https://dx.doi.org/10.2174/187152711797247885 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Current Progresses on Nanodelivery Systems for the Treatment of Neuropsychiatric Diseases: Alzheimer’s and Schizophrenia
Current Pharmaceutical Design Going up in Smoke? A Review of nAChRs-based Treatment Strategies for Improving Cognition in Schizophrenia
Current Pharmaceutical Design Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Neuroprotective Strategies for Parkinsons Disease
Current Neuropharmacology Recent Advances in Cannabis sativa Research: Biosynthetic Studies and Its Potential in Biotechnology
Current Pharmaceutical Biotechnology D1 and Functionally Selective Dopamine Agonists as Neuroprotective Agents in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Rhinosinusitis in the Pediatric Patient with Cystic Fibrosis
Current Pediatric Reviews The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Nitric Oxide Modulation of the Basal Ganglia Circuitry: Therapeutic Implication for Parkinson's Disease and Other Motor Disorders
CNS & Neurological Disorders - Drug Targets Exhaled Breath Biomarkers in Asthmatic Children
Inflammation & Allergy - Drug Targets (Discontinued) Role of Nitric Oxide in Motor Control: Implications for Parkinsons Disease Pathophysiology and Treatment
Current Pharmaceutical Design Differences in Medication Adherence, Satisfaction and Clinical Symptoms in Schizophrenic outpatients Taking Different Antipsychotic Regimens
Current Drug Safety NOS: Molecular Mechanisms, Clinical Aspects, Therapeutic and Monitoring Approaches
Current Drug Targets - Inflammation & Allergy Postoperative Delirium
Current Drug Targets New Insights on Dimethylaminoethanol (DMAE) Features as a Free Radical Scavenger
Drug Metabolism Letters Advances in Lentiviral Vectors: A Patent Review
Recent Patents on DNA & Gene Sequences